Either of Amgen's conatumumab or AMG-479 was effective in extending the lives of pancreatic cancer patients undergoing chemotherapy by one month compared with those undergoing chemo alone, researchers reported. Another study demonstrated that the company's AMG-386 stalled the progression of advanced ovarian cancer when combined with chemotherapy. "Targeted agents like 386 and 479 add to our ability to battle these diseases," Amgen Chief Medical Officer Sean Harper said. "We hope one day that these strategies will result in cures for solid tumors that currently are cured only at very early stages."

Related Summaries